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Introduction
In dialysis patients, morbidity and mortality are substantially higher than in the general population. 1, 2 There is increasing evidence suggesting that disorders of mineral metabolism, including abnormalities of plasma calcium, phosphorus, and intact parathyroid hormone (iPTH) concentrations, contribute to the development of vascular calcification and, possibly, cardiovascular disease in dialysis patients. 3, 4 It was shown in these patients that elevated phosphorus and calcium-phosphorus (Ca x P) product concentrations are associated with cardiovascular calcification, cardiac ischaemia, and an increased cardiovascular mortality rate. [5] [6] [7] [8] In 1998, Block et al. 6 found greater mortality risks for elevated phosphorus and Ca x P product concentrations in prevalent haemodialysis (HD) patients in the United States. A few years later, Ganesh et al. 7 observed similar increased mortality risks. Using data from these and other findings, the National Kidney Foundation-Kidney Disease Outcome Quality Initiative (K/DOQI) published their guideline for bone metabolism and disease in chronic kidney disease (CKD) in 2003. 9 Recommendations in this guideline are intended to assist nephrologists in developing an integrated approach to the diagnosis and management of mineral metabolism disorders. The guideline recommends measuring calcium, phosphorus, and iPTH on a regular basis, which is every month for calcium and phosphorus and every three months for iPTH. Serum concentrations of corrected calcium should be maintained between 8.4 and 9.5 mg/dl (2.10 and 2.37 mmol/l), and serum concentrations of phosphorus, between 3.5 and 5.5 mg/dl (1.13 and 1.78 mmol/l). Ca x P product concentrations should be maintained at less than 55 mg 2 /dl 2 (<4.4 mmol 2 /l 2 ). Finally, iPTH concentrations should be in the range of 150 to 300 pg/ml (ng/l).
Evidence-based guidelines ideally should be based on meta-analysis or multiple randomised controlled trials. Because these studies currently are not available, the guideline is based on observational studies and expert opinion. Therefore, more studies are required to establish the clinical relevance of these targets.
The aim of this longitudinal study is to evaluate achievement of the K/DOQI targets for calcium, phosphorus, Ca x P product, and iPTH levels and the effect of these targets on allcause mortality risk in incident HD and peritoneal dialysis (PD) patients in The Netherlands.
Methods

Patients
The Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD) is a large, prospective, multicentre, cohort study in which patients with end-stage renal disease (ESRD) are followed up from the initiation of dialysis therapy until transplantation or death. All incident ESRD patients in 38 of the 50 dialysis units in The Netherlands were consecutively invited to participate in the study. Patients had to be 18 years or older, with dialysis as their first renal replacement therapy.
For the current analysis we included HD and PD patients new on long-term dialysis treatment between 1997 and 2004. Because the greater part of the study period was before publication of the K/DOQI guideline, nephrologists probably did not aim for these targets. The resulting large variation enabled us to study the effects of K/DOQI targets on mortality. To be included, patients had to have measurements of plasma calcium, phosphorus, iPTH, and albumin available at three months after the start of dialysis (baseline). All patients gave informed consent before inclusion, and the study was approved by all local medical ethics committees. Patients were followed up until transplantation, mortality, or date of censoring (1 January 2005).
Data Collection
Data for demographics, primary kidney disease, and comorbidity were collected zero to four weeks before the start of dialysis treatment. During follow-up, data for residual renal function, biochemistry, and dialysis characteristics were collected at fixed time points: three and six months after the start of dialysis therapy, followed by six-month intervals.
Primary kidney disease was classified according to the codes of the European Renal Association-Dialysis and Transplantation Association. Patients were categorised according to Davies' comorbidity index as having no, intermediate or severe comorbidity based on number of comorbid conditions. 10 Nutritional status was scored on the seven-point scale of the Subjective Global Assessment (SGA), which is a standardised method based on the clinical judgment of the dialysis nurse. 11 Patients with an SGA score of five or less were considered as malnourished.
Residual renal function was expressed as residual glomerular filtration rate, calculated as the mean of creatinine and urea clearance adjusted for body surface area (in millilitres per minute per 1.73 m 2 ). Dialysis dose, expressed as Kt/V urea per week, was calculated as dialysis urea clearance, divided by urea distribution volume (V) according to Watson et al. 12 For HD patients, dialysis urea clearance was calculated using a second-generation Daugirdas formula 13 and for PD patients, peritoneal Kt/V urea was calculated by using 24-hour dialysate collection. Plasma calcium, phosphorus, iPTH, and albumin were measured by using standard laboratory techniques in the different centres. Calcium concentration (in milligram per decilitre) was corrected for albumin concentration (in grams per decilitre) by using the following formula: 14 Corrected calcium = calcium + 0.8 * (4 -albumin)
To calculate the Ca x P product in milligrams squared per decilitre squared, we multiplied corrected calcium concentration by phosphorus concentration, each in milligrams per decilitre.
Statistical Analysis
Standard descriptive statistics were used to examine differences between HD and PD patients. Student t-tests were applied for testing differences in continuous variables, and chi-square tests were used to compare distributions of dichotomous or categorical data.
First, we examined plasma concentrations and achievement of the K/DOQI guideline at three months after the onset of dialysis treatment. In a survival analysis based on plasma concentrations at three months after dialysis therapy initiation, a Cox proportional hazards model was used to examine effects of plasma concentrations on patient survival. Plasma concentrations were classified into categories less than, at, or greater than the targets advised by K/DOQI, and analyses were stratified for treatment modality (HD or PD) based on the therapy reported three months after start of dialysis treatment. We calculated crude and adjusted hazard ratios (HRs) for all-cause mortality, the latter with adjustment for the possible confounding effects of age, Davies comorbidity score, primary kidney disease, SGA, albumin level, Kt/V urea per week, and haemoglobin level. Supplementary adjustments for laboratory parameters related to mineral metabolism were made for phosphorus and iPTH in analyses on the effects of calcium. Similarly, we made additional adjustments for calcium and iPTH levels in analyses of phosphorus, for iPTH levels in analyses of Ca x P product, and for calcium and phosphorus levels in analyses of iPTH.
To study mineral metabolism over time, we explored plasma concentrations and achievement of targets during follow-up. We performed a time-dependent survival analysis using the Cox proportional hazards model. This time-dependent analysis was based on plasma concentrations at all available times, and the most recently measured plasma concentrations were used to predict effects on mortality in the subsequent six-month period. Again, plasma concentrations were categorised according to K/DOQI targets, and analyses were stratified for treatment modality. The multivariate model contained age, comorbidity, primary kidney disease, and nutritional status as recorded at three months after the start of dialysis therapy and calcium, phosphorus, iPTH, albumin, Kt/V urea per week, and haemoglobin as time-dependent variables.
All statistical analyses were performed using SAS statistical software, version 9.1 (SAS Institute, Cary, NC). P less than 0.05 was considered statistically significant.
Results
Description
Of 1753 patients, 1629 patients met inclusion criteria. We excluded 124 patients because of missing plasma calcium, phosphorus, iPTH or albumin levels at baseline. Diabetes mellitus and glomerulonephritis were less common causes of primary kidney disease in the excluded patients, whereas more renal vascular disease was diagnosed compared with included patients. Other baseline characteristics of these patients did not differ from those of included patients. The proportion of patients who died during the study period was greater in excluded patients compared with included patients (48% versus 36%).
Included patients had a mean age of 60 years, 61% were men, and 64% were treated with HD. Patient characteristics at three months after the start of dialysis treatment are listed in Table 1 . Compared with PD patients, HD patients were significantly older, differed in causes of primary kidney disease, and had a lower residual glomerular filtration rate. Proportions of patients with a moderate or high comorbidity score and malnutrition were greater in HD compared with PD patients.
Plasma Concentrations and Achievement of Targets
Three months after the onset of dialysis treatment, HD patients had significantly greater plasma concentrations of phosphorus and Ca x P product than PD patients. Conversely, PD patients had greater plasma calcium concentrations. In Table 1 , plasma concentrations of calcium, phosphorus, Ca x P product, and iPTH three months after dialysis therapy initiation are listed.
At this first time point three months after the start of dialysis therapy, the majority of patients had plasma calcium concentrations greater than the range prescribed by K/DOQI. Forty percent of HD patients met the guideline for calcium levels, which was significantly greater than the proportion of PD patients with plasma calcium levels within the target range (29%; P <0.001). Conversely, the percentage of HD patients that reached the phosphorus target (39%) was less than that of PD patients (50%; P <0.001), and most patients had greater plasma levels than advised. The target for Ca x P product was met by 54% of HD and 58% of PD patients. Finally, more than half the patients had plasma iPTH concentrations less than the proposed target range, and 21% of HD and 22% of PD patients reached the iPTH target. For Ca x P product and iPTH, achievement of targets did not differ between HD and PD patients. When we combined targets, we found that at three months after the start of dialysis treatment, 16% of HD and 15% of PD patients met both calcium and phosphorus targets (P =0.71). For the combination of phosphorus and Ca x P product targets, this was 36% for HD and 45% for PD patients (P <0.001). Only 4.7% of HD and 5.9% of PD patients achieved all four targets (P =0.26).
Achievement of the K/DOQI guideline in HD and PD patients is listed per year of dialysis treatment in survivors through this year in Table 2 . We observed that the percentage of HD patients with plasma calcium levels greater than the K/DOQI target increased from 53% at year one to 83% at year five. In PD patients, 69% of patients at year one had plasma calcium levels greater than the target, and this increased to 78% at year five. For plasma phosphorus, Ca x P product, and iPTH concentrations, the proportion of both HD and PD patients that met the targets remained stable during the first five years of treatment with dialysis. Table 2 . Percentages of achievement of K/DOQI-targets for calcium, phosphorus, Ca x P product and iPTH per year since start of dialysis treatment in HD and PD patients Percentages for each year represent the distribution among survivors through this year. K/DOQI guideline ranges: Serum calcium 8.4-9.5 mg/dl, serum phosphorus 3.5-5.5 mg/dl, Ca x P product <55 mg 2 /dl 2 , iPTH 150-300 pg/ml.
Survival analyses
Crude survival curves for HD and PD patients are shown in Figure 1 . Maximal follow-up was seven and a half years (1997 to 2005). Median follow-up was 28 months (2.3 years) in the HD group and 29 months (2.4 years) in the PD group. Two-year survival rates were 74% in HD and 86% in PD patients. 1  1043  7  40  53  7  39  53  54  46  56  21  23  5  2  931  3  30  67  8  42  50  53  47  62  19  19  2 We performed survival analysis based on plasma levels three months after the start of dialysis therapy. Cox regression models were used to calculate crude and adjusted HRs for all-cause mortality risk in categories of patients who had plasma levels less than, at, or greater than the advised targets. In unadjusted analyses, we could not detect an effect of plasma concentrations beyond the K/DOQI ranges on all-cause mortality risk (data not shown). In the multivariate model containing calcium level, phosphorus level, iPTH level, age, comorbidity score, primary kidney disease, nutritional status, albumin level, dialysis dose, and haemoglobin level, only a significant increased mortality risk [HR: 1.7; 95% confidence interval (CI): 1.2 to 2.5] was observed for HD patients with plasma calcium concentrations less than the target. In PD patients we found a protective effect on all-cause mortality (HR: 0.7; 95% CI: 0.4 to 1.0) of plasma calcium concentrations greater than the K/DOQI target that was borderline significant (P =0.05). Adjusted HRs are listed in Table 3 . Table 3 . Adjusted* hazard ratios (95% CI) for all-cause mortality in HD and PD patients, based on plasma concentrations three months after the start of dialysis treatment in categories prescribed in the K/DOQI guideline .95 K/DOQI guideline ranges: serum calcium 8.4-9.5 mg/dl, serum phosphorus 3.5-5.5 mg/dl, Ca x P product <55 mg 2 /dl 2 , iPTH 150-300 pg/ml. * Multivariate model contained: Calcium, phosphorus, iPTH, age, co-morbidity, primary kidney disease, nutritional status (SGA), albumin, haemoglobin, and dialysis Kt/Vurea per week.
Analyses were repeated using time-dependent Cox regression models. Again, we did not observe an effect on all-cause mortality of plasma concentrations less or greater than the K/DOQI targets in crude analyses (data not shown). Applying adjustments for confounding factors yielded an elevated all-cause mortality risk of 1.4 (95% CI: 1.1 to 1.7) in HD patients who had a phosphorus concentration greater than 5.5 mg/dl (1.78 mmol/l). In PD patients with plasma phosphorus levels greater than the target, all-cause mortality risk increased by 60% (HR: 1.6; 95% CI: 1.1 to 2.4). In addition, plasma Ca x P product levels greater than 55 mg 2 /dl 2 yielded a significantly increased HR of 1.4 (95% CI: 1.1 to1.8) in HD patients, and in PD patients with elevated Ca x P product levels, we found a 50% increased mortality risk (HR: 1.5; 95% CI: 1.0 to 2.2). Having a plasma phosphorus concentration less than the target or abnormal plasma calcium or iPTH levels did not influence patient survival. In Table 4 , results of adjusted time-dependent analyses are listed. Because 19% of patients switched therapy during the study, we repeated the analyses using a time-dependent model in which we censored patients at the time they switched treatment modality. This additional analysis did not alter our findings.
Discussion
In the current study, in time-dependent multivariate survival analyses, we observed significantly increased all-cause mortality risks for HD and PD patients who had plasma concentrations greater than the phosphorus and Ca x P product targets proposed in the recently published K/DOQI guideline for bone metabolism and disease in patients with CKD.
The proportion of patients who met the K/DOQI guideline was low. This was observed not only shortly after the onset of dialysis treatment, but also in the first five years after the start of dialysis therapy. Mean plasma calcium, phosphorus, and Ca x P product concentrations in HD and PD patients appeared to be greater than those supported by the guideline. Conversely, on average, plasma iPTH concentrations were less than advised in the guideline. We cannot determine from our study whether the low achievement of K/DOQI goals was caused by infeasibility of the targets, or that target guidelines were not available before 2003.
A limitation of this study might be that iPTH measurements were performed by using various first-generation immunometric iPTH assays, depending on the different participating centres. We are aware that these methods may yield different results.
Various studies on the effect of serum calcium, phosphorus, Ca x P product, and iPTH levels on mortality risk in dialysis patients have been published. [3] [4] [5] [6] [7] [8] In 1998, Block et al. 6 observed increased relative risks for death of 1.27 (P <0.001) for serum phosphorus levels greater than 6.5 mg/dl (>2.1 mmol/l) and 1.34 (P <0.01) for serum Ca x P product levels greater than 72 mg 2 /dl 2 (>5.8 mmol 2 /l 2 ) in 6407 prevalent HD patients from the US Renal Data System. Using the same data sources, Ganesh et al. 7 (2001) studied a population of 12833 HD patients and found increases in all-cause mortality risks for elevated phosphorus, Ca x P product, and iPTH levels. However, in these analyses, higher thresholds were used than those formulated in the guidelines, whereas the present study focused on lower limits, as proposed by K/DOQI. Moreover, the sample size of our study was notably smaller than that of the American studies. These discrepancies could explain the different results that we found in survival analyses based on baseline values in HD patients in the current study.
In the survival analysis based on plasma concentrations three months after the start of dialysis therapy, we found an increased mortality risk in HD patients for plasma calcium concentrations less than the target. We cannot explain this association. However, only a small proportion of HD patients (7%) had such low calcium concentrations. Moreover, this finding was not confirmed in the literature or in our time-dependent analysis. In our study, we observed that time-dependent survival analyses yielded stronger effects of elevated plasma concentrations on mortality risk than standard survival analyses. In time-dependent survival analyses, the most recently measured plasma concentrations were used to predict effects on mortality in the subsequent six-month period. These more recent values provide a better indication of future life expectancy than the plasma concentrations measured three months after the start of dialysis treatment that were used in the initial survival analyses. We were not able to compare our results with other studies because we could not identify prior publications of studies that used time-dependent techniques in either HD or PD patients.
Approximately 90% of the HD and PD patients in this study were administered phosphate binders. Despite this, mean phosphorus concentrations were still too high. The mean phosphorus concentration in our HD patients of 5.8 mg/dl (1.87 mmol/l) is similar to that of 5.7 mg/dl (1.84 mmol/l) observed in European dialysis centres participating in the Dialysis Outcomes and Practice Patterns Study. 5 However, these phosphorus concentrations are substantially less than the mean concentration of 6.2 mg/dl (2.00 mmol/l) found in the US Renal Data System study. 6, 7 The type of prescribed phosphate binders in our study is not known. Because non-calcium containing phosphate binders were not yet available during the greater part of the study period, we assume that the majority of the patients were administered calcium-based phosphate binders (calcium acetate or calcium carbonate). Therefore, the high plasma calcium concentrations that we observed could have been caused by the use of calcium-containing phosphate binders and prescription of vitamin D analogues. As a result of relatively high calcium levels, iPTH concentrations are suppressed. Moreover, vitamin D analogues can have a direct restraining effect on PTH-release. 15, 16 However, no data on the use of vitamin D analogues were available. It is unlikely that extirpation of the parathyroid glands had an influence on mean iPTH concentration because only 67 patients (4.1%) underwent subtotal or total parathyroidectomy during the study period.
In conclusion, having plasma phosphorus or Ca x P product concentrations greater than the targets prescribed in the K/DOQI guideline for bone metabolism and disease in CKD increased all-cause mortality risk significantly and independently in HD and PD patients in The Netherlands.
